Literature DB >> 19965850

Large-scale SOD1 mutation screening provides evidence for genetic heterogeneity in amyotrophic lateral sclerosis.

Michael A van Es1, Caroline Dahlberg, Anna Birve, Jan Herman Veldink, Leonard H van den Berg, P M Andersen.   

Abstract

OBJECTIVE: To estimate the frequency of SOD1 mutations in a large referral cohort of familial amyotrophic lateral sclerosis (FALS) and sporadic amyotrophic lateral sclerosis (SALS) patients from The Netherlands and to compare this frequency with that of other developed countries.
METHODS: A total of 451 sporadic and 55 FALS patients were screened for SOD1 mutations. The authors performed PCR amplification of all five coding exons of SOD1 followed by direct DNA sequencing using forward and reverse primers.
RESULTS: One novel mutation (p.I99V) and a homozygous p.D90A mutation were identified in SALS patients. In a pedigree with Mendelian dominant FALS, one patient was found to be heterozygous for the p.D90A mutation. SOD1 mutation frequency was found to be significantly lower in The Netherlands compared with other countries with p=0.0004 for FALS (21.9% vs 2.5%) and p=0.005 for SALS (2.5% vs 0.44%).
CONCLUSIONS: The authors demonstrate that SOD1 mutations are rare in The Netherlands in familial and SALS. This observation suggests that the genetic background of amyotrophic lateral sclerosis differs between different populations, countries and regions. This may have consequences for the interpretation of association studies and explain why replication of association studies has proven difficult in amyotrophic lateral sclerosis.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19965850     DOI: 10.1136/jnnp.2009.181453

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN: 0022-3050            Impact factor:   10.154


  21 in total

1.  P413L CHGB is not associated with ALS susceptibility or age at onset in a Dutch population.

Authors:  Paul W J van Vught; Jan H Veldink; Leonard H van den Berg
Journal:  Proc Natl Acad Sci U S A       Date:  2010-04-29       Impact factor: 11.205

Review 2.  Familial Amyotrophic Lateral Sclerosis.

Authors:  Kevin Boylan
Journal:  Neurol Clin       Date:  2015-09-08       Impact factor: 3.806

Review 3.  Clinical and demographic factors and outcome of amyotrophic lateral sclerosis in relation to population ancestral origin.

Authors:  Benoît Marin; Giancarlo Logroscino; Farid Boumédiene; Anaïs Labrunie; Philippe Couratier; Marie-Claude Babron; Anne Louise Leutenegger; Pierre Marie Preux; Ettore Beghi
Journal:  Eur J Epidemiol       Date:  2015-10-12       Impact factor: 8.082

4.  Homozygous SMN2 deletion is a protective factor in the Swedish ALS population.

Authors:  Philippe Corcia; Caroline Ingre; Helene Blasco; Rayomand Press; Julien Praline; Catherine Antar; Charlotte Veyrat-Durebex; Yves-Olivier Guettard; William Camu; Peter M Andersen; Patrick Vourc'h; Christian R Andres
Journal:  Eur J Hum Genet       Date:  2012-01-25       Impact factor: 4.246

Review 5.  Clinical genetics of amyotrophic lateral sclerosis: what do we really know?

Authors:  Peter M Andersen; Ammar Al-Chalabi
Journal:  Nat Rev Neurol       Date:  2011-10-11       Impact factor: 42.937

6.  Amyotrophic lateral sclerosis: update and new developments.

Authors:  Ashley J Pratt; Elizabeth D Getzoff; J Jefferson P Perry
Journal:  Degener Neurol Neuromuscul Dis       Date:  2012-02

7.  Dysregulation of a novel miR-1825/TBCB/TUBA4A pathway in sporadic and familial ALS.

Authors:  Anika M Helferich; Sarah J Brockmann; Jörg Reinders; Dhruva Deshpande; Karlheinz Holzmann; David Brenner; Peter M Andersen; Susanne Petri; Dietmar R Thal; Jens Michaelis; Markus Otto; Steffen Just; Albert C Ludolph; Karin M Danzer; Axel Freischmidt; Jochen H Weishaupt
Journal:  Cell Mol Life Sci       Date:  2018-07-20       Impact factor: 9.261

8.  The molecular tweezer CLR01 inhibits aberrant superoxide dismutase 1 (SOD1) self-assembly in vitro and in the G93A-SOD1 mouse model of ALS.

Authors:  Ravinder Malik; Helen Meng; Piriya Wongkongkathep; Christian I Corrales; Niki Sepanj; Ryan S Atlasi; Frank-Gerrit Klärner; Thomas Schrader; Melissa J Spencer; Joseph A Loo; Martina Wiedau; Gal Bitan
Journal:  J Biol Chem       Date:  2019-01-02       Impact factor: 5.157

Review 9.  Examining the relationship between astrocyte dysfunction and neurodegeneration in ALS using hiPSCs.

Authors:  Madeline Halpern; Kristen J Brennand; James Gregory
Journal:  Neurobiol Dis       Date:  2019-08-02       Impact factor: 5.996

10.  Mutations in CHMP2B in lower motor neuron predominant amyotrophic lateral sclerosis (ALS).

Authors:  Laura E Cox; Laura Ferraiuolo; Emily F Goodall; Paul R Heath; Adrian Higginbottom; Heather Mortiboys; Hannah C Hollinger; Judith A Hartley; Alice Brockington; Christine E Burness; Karen E Morrison; Stephen B Wharton; Andrew J Grierson; Paul G Ince; Janine Kirby; Pamela J Shaw
Journal:  PLoS One       Date:  2010-03-24       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.